Download

Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery






Advertisement
/ 40 []
Download Presentation
Comments
channary
From:
|  
(116) |   (0) |   (0)
Views: 189 | Added:
Rate Presentation: 1 0
Description:
Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery Director ; Diabetes Surgery Center Weill Cornell Medical College - New York Presbyterian Hospital New York, NY USA.
Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery

An Image/Link below is provided (as is) to

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime. While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.











- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -




Slide1 l.jpgSlide 1

EndoluminalDuodenal-JejunalSleeve, Fat Reduction... And the Future

Francesco Rubino, MD

Chief, Section of GastrointestinalMetabolicSurgery

Director; DiabetesSurgeryCenter

Weill CornellMedicalCollege- New York PresbyterianHospital

New York, NY USA

First Canadian Summit on Metabolic Surgery for T2DM

Montreal, May 6-7, 2010

Methods l.jpgSlide 2

METHODS

Intraluminal Duodenal Sleeve

Controls fenestrated duodenal sleeve l.jpgSlide 3

Controls: Fenestrated Duodenal Sleeve

Slide4 l.jpgSlide 4

Fig 1 b

Goto kakizaki rat gk l.jpgSlide 5

Goto-Kakizaki Rat (GK)

  • Complete tube (n=12)

  • Fenestrated Tube (n=12)

  • No tube (Sham) (n=6)

    2 & 3 pair-fed to 1

Slide6 l.jpgSlide 6

OGTT

AUC: P< 0.01

Slide7 l.jpgSlide 7

« Larry »

Slide8 l.jpgSlide 8

« Larry »

Slide9 l.jpgSlide 9

« Larry »

Slide10 l.jpgSlide 10

« Larry »

Slide11 l.jpgSlide 11

« Larry »

Gk rats gip response to glucose l.jpgSlide 12

GK Rats: GIP-Response to Glucose

Wistar rats gip response to glucose l.jpgSlide 13

Wistar Rats: GIP-Response to Glucose

Els improves ip glucose tolerance kaplan et al l.jpgSlide 14

ELS Improves IP Glucose Tolerance (Kaplan et al)

Endoluminal sleeve endobarrier l.jpgSlide 15

Endoluminal Sleeve - EndoBarrier™

Food bypasses the duodenum and proximal jejunum

CONFIDENTIAL

Week 1 data summary l.jpgSlide 16

Week 1 Data Summary

EndoBarrier™ Diabetes Trial (Chile)

*Food intake held identical

Endobarrier improves hba1c l.jpgSlide 17

EndoBarrier™ Improves HbA1c

EndoBarrier™ Diabetes Trial (Chile)

Week 12

Week 30

N=9

N=4

N=8

N=3

*Week 30 p=0.004

Endoluminal sleeve mechanisms l.jpgSlide 18

Endoluminal Sleeve: Mechanisms

  • Isolation of Duodenal Mucosa from Nutrients Contact

  • Bile isolated from nutrients

  • No expedited delivery of nutrients to the distal gut

Endoluminal sleeve clinical applications l.jpgSlide 19

Endoluminal Sleeve: Clinical Applications

  • Primary Therapy of Diabetes ?

    • Long-term ?

    • BMI> 35 ?

    • BMI < 35 ?

  • Diagnostic value ?

  • Pre-surgical Test to select candidates for gastric bypass surgery

  • Integrated Interventional-Drug approach

    • “Adjuvant Therapy”

Endobarrier weight loss results at 6 months l.jpgSlide 20

EndoBarrier Weight Loss Results At 6 Months

Endobarrier glucose improvement at 6 months l.jpgSlide 21

EndoBarrier Glucose Improvement at 6 Months

Surgery adiposity and diabetes l.jpgSlide 22

Surgery, Adiposity and Diabetes

Liposuction does not improve diabetes

Surgical resection of greater omentum does not resolve diabetes

S. Klein et al. (ADA 2009)

Metabolic surgery the future l.jpgSlide 23

Metabolic Surgery… the future

  • Multidisciplinary approach and guidelines/standards of care development

Slide24 l.jpgSlide 24

Annals of Surgery; March 2010

Slide26 l.jpgSlide 26

DSS Reccommendations are

Endorsed by:

ASMBS

IFSO

The Obesity Society (TOS)

Int. Ass Study of Obesity (IASO)

Diabetes UK

Slide27 l.jpgSlide 27

  • Bariatric surgery should be considered for adults with BMI > 35 kg/m2 and type 2 diabetes, especially if the diabetes is difficult to control with lifestyle and pharmacologic therapy. (B)

  • Surgery should be considered in pts with BMI > 35 and inadequately controlled diabetes.

Slide28 l.jpgSlide 28

  • in patients with type 2 diabetes and BMI of 30–35kg/m2, there is currently insufficient evidence to generally recommend surgery in patients with BMI35 kg/m2 outside of a research protocol.

  • Surgery may be considered as a non-primary alternative in pts with uncontrolled diabetes and BMI 30-35.

Metabolic surgery the future29 l.jpgSlide 29

Metabolic Surgery… the future

  • Solving the BMI issue…

Slide30 l.jpgSlide 30

DSS- BMI

  • Controlled clinical trials in these patients should be performed to determine the safety and efficacy of GI metabolic surgery (A) as well as to identify parameters other than BMI as criteria for appropriate patient selection (A).

SAME LANGUAGE IN ADA’ STANDARDS OF CARE DOCUMENT

Slide31 l.jpgSlide 31

Diabetologia 1996

Metabolic surgery the future32 l.jpgSlide 32

Metabolic Surgery… the future

  • Solving the BMI issue…

  • Diabetes-specific criteria for surgical indication

  • Risk-Stratification in diabetes

  • Improve Standards of Clinical Research

Patient factors and outcomes associated with t2dm resolution n 191 l.jpgSlide 33

Patient Factors and Outcomes Associated with T2DM Resolution (N=191)

Schauer et al. Annals of Surgery Oct 2003

Slide34 l.jpgSlide 34

The “Bad Reputation” of Bariatric Surgery

* Any Textbook

Slide35 l.jpgSlide 35

DSS- Research

  • Randomized controlled trials are strongly encouraged to assess the utility of GI surgery to treat T2DM (A). In patients with BMI <35 kg/m2, determining the appropriate use of GI surgery for the treatment of T2DM is an important research priority (A).

Slide36 l.jpgSlide 36

Worldwide Consortium for RandomizedClinical Trials in DiabetesSurgery

(WORLDCords)

Diabetes Surgery Center

Weill CornellMedicalCollege-New York PresbyterianHospital

Slide37 l.jpgSlide 37

Cornell’s Study

RYGB (Lap)

vs

MedicalTherapy and Lifestyle Modification

PI: Francesco Rubino

SteeringCommittee: H. Lebovitz, J. Buse, A. Goldfine, J. Roth B. Zinman, B. Wolfe, JP Despres, S. Belle

Participating countries l.jpgSlide 38

Participating Countries

REGIONAL Chapters:

  • Europe (centers already available in Italy, Netherlands, Belgium, Spain, England,)

  • South-Central America (Mexico?, Brasil, Argentina, Chile, Venezuela,)

  • North America (Cornell, Tuffs, Univ. of Maryland, Mount Sinai?)

  • Asia (Philippines, India, Taiwan, Japan)

  • Middle East (Quatar, UAE, SA)

Slide39 l.jpgSlide 39

International Consortium for Diabetes Surgery

Weill Cornell –NYP

Study (50 pts)

US Multicenter Study

200 patients

Worldwide Consortium for RCT

500-800 pts

Metabolic surgery the future40 l.jpgSlide 40

Metabolic Surgery… the future

  • Solving the BMI issue…

  • Diabetes-specific criteria for surgical indication

  • Risk-Stratification in diabetes

  • Improve Standards of Clinical Research

  • Elucidation of Mechanisms of Action

    • Novel Surgical Procedures

    • Endoluminal Approaches

    • Novel Targets for Drugs

      Re-thinking of Diabetes and Obesity


Copyright © 2014 SlideServe. All rights reserved | Powered By DigitalOfficePro